BACKGROUND
ORCHARD (NCT03944772) was a biomarker-directed, phase II, platform study conducted to characterize resistance mechanisms and evaluate novel treatment combinations in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) following progression on first-line osimertini...
J. Goldman, J. W. Riess, Byoung Chul Cho et al.· Clinical Lung Cancer· 0 citations
PURPOSE
A structure-function classification has defined epidermal growth factor receptor (EGFR) P-loop/αC-helix compressing (PACC) mutations and exon 20 insertions (ex20ins) as distinct subsets of kinase domain EGFR alterations. Lung cancers harboring those mutations display reduced sensitivity to EGFR tyrosine kinase...
F. Monaca, I. Randulfe, J. Heymach et al.· Journal of Clinical Oncology· 0 citations
A multidisciplinary panel of oncology experts convened to review current evidence gaps, controversies, and unmet needs in the management of lung cancer, highlighting the need for prospective, head‐to‐head clinical trials.
N. Florez, S. Patel, R. Salgia et al.· Cancer· 1 citation
This study aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC whose disease progressed after third-generation EGFR tyrosine kinase inhibitor (TKI) therapy.
X. Le, A. Passaro, Yuan-Yuan Zhao et al.· The Lancet Oncology· 0 citations
Findings support sutetinib as a potential treatment option for this molecularly heterogeneous population of adults with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations and demonstrate clinically meaningful antitumor activity with a manageable safety profile.
Feng-Ying Wu, Wei Zhang, Yan-Qiu Zhao et al.· Journal of Thoracic Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.